



DT06Recd PCT 09 DEC 2002  
Docket No.: PF-0610 USN

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Office of Initial Patent Examination, Filing Receipt Corrections, Customer Service Center Washington, D.C. 20231 on December 2, 2002

By: D. Ellis Printed: D. Ellis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Lal et al.

Title: OXIDOREDUCTASE MOLECULES

Serial No.: 09/806,536

Filing Date: March 28, 2001

Examiner: To Be Assigned

Group Art Unit: 1645

Commissioner for Patents  
Office of Initial Patent Examination  
Filing Receipt Corrections  
Customer Service Center  
Washington, D.C. 20231

RECEIVED  
JAN 21 2003  
TECH CENTER 1600/2900

**TRANSMITTAL FEE SHEET**

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Request for Corrected Filing Receipt (2 pp.);
3. Copy of official Filing Receipt (2 pp.);
4. Copy of Patent Application Transmittal (2 pp.);
5. Copy of executed Declaration and Power of Attorney (7 pp.);
6. Associate Power of Attorney (1 pg.); and
7. Limited Recognition (1 pg.).

The fee has been calculated as shown below.

X No additional Fee is required.

       Please charge Deposit Account No. **09-0108** in the amount of: \$       

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: December 2, 2002

Terence P. Lo  
Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached  
Direct Dial Telephone: (650) 621-8581

Customer No.: 27904  
3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

103694

1

09/806,536



Docket No.: PF-0610 USN

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Office of Initial Patent Examination, Filing Receipt Corrections, Customer Service Center Washington, D.C. 20231 on December 2, 2002.

By: [Signature]

Printed: D. Ellis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: OXIDOREDUCTASE MOLECULES

Serial No.: 09/806,536

Filing Date: March 28, 2001

Examiner: To Be Assigned

Group Art Unit: 1645

RECEIVED  
JAN 21 2003  
TECH CENTER 1600/2900

Commissioner for Patents  
Office of Initial Patent Examination  
Filing Receipt Corrections  
Customer Service Center  
Washington, D.C. 20231

REQUEST FOR A CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the Official Filing Receipt (with red-line markings to note changes) received from the United States Patent and Trademark Office (USPTO) in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

1. Under the section entitled "Applicant(s)," please replace "Henry Sue" with --Henry Yue--.

Applicants hereby request that the above corrections be entered based on the following enclosed documents:

1. A copy of the Patent Application Transmittal (2 pp.); and
2. A copy of the executed Declaration (7 pp.).

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: December 2, 2002

Terry Lo  
Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached

Direct Dial Telephone: (650) 621-8581

Customer No. 27904  
3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166



Incyte Pharmaceuticals, Inc.  
Patent Department  
Received

NOV 25 2002

Page 1 of 2

COPY

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/806,536	03/28/2001	1645	690	PF-0610 USN		20	2

CONFIRMATION NO. 1220

Incyte Genomics Inc  
Legal Department  
3160 Porter Drive  
Palo Alto, CA 94304

FILING RECEIPT



\*0C000000009111025\*

Date Mailed: 11/15/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Preeti Lal, Santa Clara, CA;  
Karl J. Guegler, Menlo Park, CA;  
Gina A. Gorgone, Boulder Creek, CA;  
Neil C. Corley, Castro Valley, CA;  
Mariah R. Baughn, San Leandro, CA;  
Y. Tom Tang, San Jose, CA;  
Jennifer L. Hillman, Mountain View, CA;  
Olga Bandman, Mountain View, CA;  
Yalda Azimzai, Castro Valley, CA;  
Janice Au-Young, Brisbane, CA;  
Henry ~~So~~ Sunnyvale, CA;  
Dyung Aina M. Lu, San Jose, CA;  
Junming Yang, San Jose, CA;

RECEIVED  
JAN 21 2003  
TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US99/23434 10/06/1999

Foreign Applications

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No



Oxidoreductase molecules

Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



# COPY

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PF-0610 USN
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TO BE ASSIGNED
INTERNATIONAL APPLICATION NO. PCT/US99/23434	INTERNATIONAL FILING DATE 06 October 1999	PRIORITY DATE CLAIMED 06 October 1998
TITLE OF INVENTION OXIDOREDUCTASE MOLECULES		
APPLICANT(S) FOR DO/EO/US INCYTE PHARMACEUTICALS, INC.; LAL, Preeti; GUEGLER, Karl J.; GORGONE, Gina A.; CORLEY, Neil C.; BAUGHN, Mariah R.; TANG, Y. Tom; BILLMAN, Jennifer L.; OLGA, Bandman; AZIMZAI, Yalda; AU-YOUNG, Janice; YUE, Henry; LU, Dyung Aina M.; YANG, Junming		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. <input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)). 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau) b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 16 below concern document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information:  1) Transmittal Letter (2 pp. in duplicate) 2) Return Postcard 3) Express Mail Label No.: <u>EL 856 113 359 US</u>		



U.S. APPLICATION NO. (If applicable, see 37 CFR 1.5) TO BE ASSIGNED		INTERNATIONAL APPLICATION NO.: PCT/US99/21434		ATTORNEY'S DOCKET NUMBER PF-0610 USN	
<p>17. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p>					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$690.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 =	18	X \$ 18.00	\$	
Independent Claims	2 =	0	X \$ 80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			= \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$690.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$690.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$690.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$690.00	
				Amount to be Refunded:	\$
				Charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$ <u>690.00</u> to cover the above fees. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>09-0108</u>. A duplicate copy of this sheet is enclosed.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>INCYTE GENOMICS, INC. 3160 Porter Drive Palo Alto, CA 94304</p> <p>SIGNATURE: </p> <p>NAME: Diana Hamlet-Cox</p> <p>REGISTRATION NUMBER: 33,302</p> <p>DATE: <u>28</u> March 2001</p>					